EXEL250117C3000
- 18.75
- 0.000.00%
Exelixis Newsroom
Brookline Capital Initiates Exelixis(EXEL.US) With Buy Rating, Announces Target Price $40
BMO Capital Downgrades Exelixis(EXEL.US) to Hold Rating, Raises Target Price to $40
Exelixis Price Target Raised to $39.00/Share From $35.00 by B of A Securities
Exelixis Cut to Neutral From Buy by B of A Securities
Exelixis Analyst Ratings
BofA Securities Downgrades Exelixis(EXEL.US) to Hold Rating, Announces Target Price $39
Leerink Partners Maintains Exelixis(EXEL.US) With Hold Rating
RBC Capital Sticks to Their Buy Rating for Exelixis (EXEL)
A Quick Look at Today's Ratings for Exelixis(EXEL.US), With a Forecast Between $29 to $38
Exelixis Price Target Raised to $36.00/Share From $32.00 by Wells Fargo
Exelixis Is Maintained at Outperform by BMO Capital
Exelixis Analyst Ratings
A Quick Look at Today's Ratings for Exelixis(EXEL.US), With a Forecast Between $29 to $38
Exelixis Analyst Ratings
TD Cowen Maintains Exelixis(EXEL.US) With Buy Rating, Raises Target Price to $34
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), Korro Bio (KRRO) and Vertex Pharmaceuticals (VRTX)
A Quick Look at Today's Ratings for Exelixis(EXEL.US), With a Forecast Between $30 to $34
A Quick Look at Today's Ratings for Exelixis(EXEL.US), With a Forecast Between $27 to $34
Morgan Stanley Lifts Price Target on Exelixis to $30 From $28, Keeps Equalweight Rating
Exelixis Is Maintained at Market Outperform by JMP Securities